MTT Assay for Chemosensitivity Testing in Ovarian Cancer
Author Information
Author(s): J.K. Wilson, J.M. Sargent, A.W. Elgie, J.G. Hill, C.G. Taylor
Primary Institution: Pembury Hospital
Hypothesis
Can the MTT assay be used effectively for chemosensitivity testing in ovarian malignancy?
Conclusion
The MTT assay is feasible for chemosensitivity testing in ovarian cancer and shows a high percentage of successful results.
Supporting Evidence
- 95% of ascitic fluid samples had viable malignant cells.
- 91% of patients had assessable drug effects.
- Platinum and anthraquinone drugs showed the greatest effect.
Takeaway
Researchers tested a method to see how well cancer cells respond to drugs, and it worked well for most patients.
Methodology
The study involved collecting ascitic fluid and tumor biopsies from patients, preparing cell suspensions, and testing drug effects using the MTT assay.
Potential Biases
Potential contamination by non-malignant cells could affect results.
Limitations
Some samples were unsuitable for testing due to contamination or insufficient malignant cells.
Participant Demographics
Patients with FIGO stage III-IV ovarian adenocarcinoma, none had prior treatment.
Want to read the original?
Access the complete publication on the publisher's website